Myeloproliferative Neoplasms

John O. Mascarenhas, MD, discusses the promise of imetelstat in myelofibrosis.

Myelodysplastic syndrome is a challenging and complicated disease with median outcomes ranging from 5.3 years in patients with lower-risk disease to just 8.4 months in the very high-risk population.

John O. Mascarenhas, MD, discusses limitations with JAK inhibitors in myelofibrosis.

Ruben A. Mesa, MD, discusses management strategies for patients with myeloproliferative neoplasms.

Lucia Masarova, MD, discusses future research ​efforts in myeloproliferative neoplasms.

Ruben A. Mesa, MD, discusses the rationale for the earlier use of ruxolitinib in myelofibrosis.

Aziz Nazha, MD, discusses risk stratification in polycythemia vera, options that have emerged for patients, approaches to consider following hydroxyurea, and the need for agents that will reverse fibrosis in the bone marrow.

Prithviraj Bose, MD, discusses current treatment options for essential thrombocythemia.

Ruben A. Mesa, MD, discusses remaining challenges faced in the treatment of patients with myeloproliferative neoplasms.

Aziz Nazha, MD, discusses the potential role of ropeginterferon alfa-2b in polycythemia vera.

A rolling submission of a new drug application for the JAK2/FLT3 inhibitor pacritinib has been initiated for patients with myelofibrosis and severe thrombocytopenia defined as platelet counts of less than 50,000 μL.

Raajit K. Rampal, MD, PhD, discusses available tools to estimate prognosis in myelofibrosis.

Aziz Nazha, MD, discusses the risk of progression to myelofibrosis in patients with polycythemia vera.

Naveen Pemmaraju, MD, discusses the potential role of novel therapies in myeloproliferative neoplasms.

Srdan Verstovsek, MD, PhD, discusses the different phases of myeloproliferative neoplasms.

Lucia Masarova, MD, discusses the toxicities associated with the combination of JAK inhibitors and other targeted therapies in patients with myelofibrosis.

An agreement has been reached to submit a new drug application for the potential accelerated approval of the JAK2/FLT3 inhibitor pacritinib for use in patients with myelofibrosis and severe thrombocytopenia.

Raajit K. Rampal, MD, PhD, discusses challenges with targeting high-risk mutations in patients with myelofibrosis.

John O. Mascarenhas, MD, discusses the need to develop curative therapies in myelofibrosis.

The myelofibrosis paradigm is bursting with novel agents and combinations that have been developed with the ultimate goal of helping patients live longer.

Raajit K. Rampal, MD, PhD, discusses the evolving understanding of genetic alterations in myeloproliferative neoplasms.

The presence of RAS/CBL mutations was found to be associated with adverse phenotypic features and survival outcomes in patients with myelofibrosis.

Emerging evidence suggests that clinical variables should not be the only consideration in prognostic and risk stratification scoring systems; genomically informed tools carry equal, if not refined, insights regarding patient outcomes.

Ruben A. Mesa, MD, discusses emerging therapies in myelofibrosis.

Prithviraj Bose, MD, discusses novel agents under investigation in essential thrombocythemia.

Omar Alkharabsheh, MD, discusses novel agents under exploration in the field of myelofibrosis.

Naveen Pemmaraju, MD, discusses the need to develop novel therapies in myeloproliferative neoplasms.

Jerry L​e Pow Spivak, MD, discusses the prevalence of polycythemia vera.  

Ruben A. Mesa, MD, discusses the emergence of JAK inhibitors in myelofibrosis. 

John O. Mascarenhas, MD, discusses the potential role of pacritinib in myeloproliferative neoplasms.